U

University of Miami | Bascom Palmer Eye Institute

Research site
(Unclaimed)
Location
1638 NW 10th Avenue, Room 201-A, Miami, Florida, United States of America
Site insights

Top conditions

Macular Degeneration (22 trials)

Eye Diseases (10 trials)

Glaucoma (8 trials)

Geographic Atrophy (7 trials)

Graves Ophthalmopathy (6 trials)

Top treatments

Ranibizumab
APL-2
Pegcetacoplan
Linsitinib
Bevacizumab
LX201
GT005
Ripasudil
Pegaptanib
Lidocaine

Parent organization

This site is a part of University of Miami

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

15 of 84
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Phase 2b Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

The overall study objective is to continue to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of linsitinib in subjects who were...

Enrolling
Thyroid Diseases
Graves Ophthalmopathy
Drug: linsitinib

The overall objective is to study the safety, pharmacokinetics and efficacy of linsitinib (a small molecule IGF-1R inhibitor) administered orally twi...

Enrolling
Thyroid Diseases
Graves Ophthalmopathy
Drug: Linsitinib
Drug: Placebo

This Phase 2 study is a non-randomized, open-label, study of the safety of AGTC-501 in participants with XLRP who have previously been treated with a...

Invitation-only
X-Linked Retinitis Pigmentosa
Biological: AGTC-501 (high dose and standard corticosteroid regimen)
Biological: AGTC-501 (low dose and standard corticosteroid regimen)
Locations recently updated

A study to assess the safety and efficacy of K-321 in participants with FECD after descemetorhexis.

Enrolling
Fuchs Endothelial Corneal Dystrophy
Drug: Placebo
Drug: Ripasudil
Locations recently updated

A study to assess the safety and efficacy of K-321 in participants with FECD after simultaneous cataract surgery and descemetorhexis.

Enrolling
Fuchs Endothelial Corneal Dystrophy
Drug: Placebo
Drug: Ripasudil

This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with g...

Active, not recruiting
Geographic Atrophy Secondary to Age-related Macular Degeneration
Drug: PEGCETACOPLAN (APL-2)

This study will evaluate the safety and tolerability of ATSN-201 in male subjects ≥ 6 years of age with RS1-associated X-linked retinoschisis (XLRS).

Enrolling
X-linked Retinoschisis
Biological: ATSN-201

The purpose of this clinical study is to evaluate the safety and efficacy of two doses of GT005 administered as a single subretinal injection in subj...

Active, not recruiting
Dry Age-related Macular Degeneration
Drug: GT005; Low Dose
Drug: GT005; High Dose

The purpose of this clinical study is to evaluate the safety and efficacy of two doses of GT005 administered as a single subretinal injection in subj...

Active, not recruiting
Dry Age-related Macular Degeneration
Drug: GT005: Medium Dose
Drug: GT005: High Dose

The purpose of the study is to determine the safety and efficacy of brief intraoperative corneal endothelial graft incubation in plasma rich in growt...

Begins enrollment this month
Corneal Edema
Fuchs' Endothelial Dystrophy
Procedure: PRGF

In this early feasibility trial the safety and performance of the new retinal prothesis PRIMA is tested in five subjects suffering from atrophic dry...

Active, not recruiting
Dry Age-related Macular Degeneration
Device: PRIMA

A phase 2 study, aiming to evaluate the efficacy, safety and pharmacokinetics of REC 0/0559 in treatment of Neurotrophic Keratitis in Adult Patient i...

Enrolling
Neurotrophic Keratitis
Other: Vehicle
Drug: Udonitrectag

The purpose of this study is to evaluate the safety, tolerability and efficacy of a single escalating doses of EDIT-101 administered via subretinal i...

Active, not recruiting
Eye Diseases, Hereditary
Inherited Retinal Dystrophies
Drug: EDIT-101

This is a Phase 1/2 Study to Assess the Safety and Efficacy of OCU410ST for Stargardt Disease.This is a multicenter study, which will be conducted in...

Enrolling
Stargardt Disease
Genetic: OCU410ST

This is a double-masked, randomized, parallel-assignment, multicenter trial examining the safety and tolerability of teprotumumab in the treatment of...

Active, not recruiting
Thyroid Eye Disease
Drug: Teprotumumab
Drug: Placebo

Trial sponsors

University of Miami logo

University of Miami (16 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems